FDX
29
-21
CNX
80
4
DE
53
8
ORLY
57
-3
ESS
60
-8
KEY
51
-3
GOOG
67
2
NKE
46
12
PRGO
44
-2
ALL
61
-2
VRSK
35
-3
MLM
53
-5
MMC
58
-2
NI
65
2
MSI
72
2
HRL
30
-5
FMC
40
4
NWSA
47
-2
VZ
47
2
SBUX
41
-3
FDX
29
-21
CNX
80
4
DE
53
8
ORLY
57
-3
ESS
60
-8
KEY
51
-3
GOOG
67
2
NKE
46
12
PRGO
44
-2
ALL
61
-2
VRSK
35
-3
MLM
53
-5
MMC
58
-2
NI
65
2
MSI
72
2
HRL
30
-5
FMC
40
4
NWSA
47
-2
VZ
47
2
SBUX
41
-3
Financhill
Back

4D Molecular Therapeutics 10K Form

Sell
11

FDMT
4D Molecular Therapeutics

Last Price:
11.61
Seasonality Move:
44.72%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2021-03-25 10K FDMT/4D Molecular Therapeutics Annual

Receive FDMT News And Ratings

See the #1 stock for the next 7 days that we like better than FDMT

FDMT Financial Statistics

Sales & Book Value

Annual Sales: $20.72M
Cash Flow: $-30.59M
Price / Cash Flow: 0
Annual Sales: $11.33
Price / Book: 1.05

Profitability

EPS (TTM): -2.30000
Net Income (TTM): $-109.89M
Gross Margin: --
Return on Equity: -25.54%
Return on Assets: -23.85%

4D Molecular Therapeutics Earnings Forecast

Key 4D Molecular Therapeutics Financial Ratios

  • The Research & Development expenses have been 468.54% of Revenue.
  • The Net Earning history of FDMT is -486.59% of Total Revenues.
  • Per Share Earnings over the last 7 years have been positive in 2 years.

4D Molecular Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: FDMT
CUSIP: 35104E
Website: 4dmoleculartherapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 28.48
Quick Ratio: 27.93

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

FDMT Technical Analysis vs Fundamental Analysis

Sell
11
4D Molecular Therapeutics (FDMT) is a Sell

Is 4D Molecular Therapeutics a Buy or a Sell?